Disease: Invasive fungal infections

Pan-Indian Clinical Registry of Invasive Fungal Infections Among Patients in the Intensive Care Unit: Protocol for a Multicentric Prospective Study

mycolabadmin

Fungal infections are a serious hidden threat in hospital intensive care units, particularly for patients with weakened immune systems. This study establishes India’s first comprehensive database system to track fungal infections across 8 major medical centers nationwide. By collecting detailed information about these infections and how they respond to treatments, the research aims to help doctors diagnose and treat fungal infections faster and more effectively. The findings will guide better clinical practices and public health policies to combat these often-neglected but deadly infections.

Read More »

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

mycolabadmin

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Read More »

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

mycolabadmin

Isavuconazole is an antifungal medication used to treat serious fungal infections that can occur in people with weakened immune systems. This research review looked at three clinical trials comparing isavuconazole to other antifungal drugs and found it works just as well while being easier on the liver. Notably, isavuconazole caused fewer drug-related side effects and liver problems compared to voriconazole, another common antifungal drug.

Read More »

In vitro activity of SF001: a next-generation polyene versus amphotericin B

mycolabadmin

This study tested a new antifungal drug called SF001 against a well-established antifungal called amphotericin B. Researchers tested both drugs against common fungal infections affecting vulnerable patients. SF001 was found to work as well as or better than amphotericin B, particularly against harder-to-treat Aspergillus fungi, while potentially causing fewer side effects.

Read More »

Occurrence of Pathogenic and Allergenic Molds in the Outdoor and Indoor Environment of a Major Hospital and Molecular Epidemiology of Aspergillus fumigatus in Kuwait

mycolabadmin

Researchers in Kuwait found many types of mold in and around a hospital, with some being resistant to common antifungal medications. They discovered that the same mold species were found both outdoors and in the hospital environment, suggesting patients could catch infections from the surrounding air. The study identified molds that could cause serious infections in vulnerable patients and found that about 10% of environmental samples contained drug-resistant strains that were also found in sick patients.

Read More »
Scroll to Top